Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Scorr-Insert
    X

    Find Novel Neurology Drugs in Preclinical Development in CANADA

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Alpha Cognition

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              9th Annual HPAPI Summit 2020

              Participation Not Confirmed

              Update your events

              Alpha Cognition Inc. Announces Granted EU Patents and Orphan Drug Designation for Its Progranulin Platform

              Contact the Supplier

              Lead Product(s): Alpha-602

              Therapeutic Area: Neurology

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 12, 2020

              Details:

              Alpha Cognition has been granted 2 EU patents relating to the use of progranulin to treat neurodegenerative diseases. Progranulin, alpha-602, is a protein, capable of protecting stressed neurons.

              ZYUS Life Sciences

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              9th Annual HPAPI Summit 2020

              Participation Not Confirmed

              Update your events

              ZYUS and University of Saskatchewan Partner to Conduct Cannabinoid-Based Research on Possible Treatment of Brain Disorders

              Contact the Supplier

              Lead Product(s): Cannabis derivatives

              Therapeutic Area: Neurology

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 07, 2020

              Details:

              Pre-clinical study seeks to determine the impact of cannabis derivatives on mental health conditions.

              PharmaCompass__DigitalAd